Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > PRAC recommendations on signals

Adopted at the 5-8 July 2021 PRAC meeting

Philippe Calandra 13 August 2021 All news
  • ← Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5 August 2021
  • Reporting of local drug related safety report, progress report and final study report in clinical trial – Hong Kong →

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

In partnership with the region

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • The ANSM publishes its haemovigilance report for 2023
  • User’s booklet – ANSM
  • Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28-31 October 2024
Copyright © 2018 - Pharmya - Legal terms - Quality Policy